图书简介 馆藏图书馆

1 Pedro Romero and Pierre G. Coulie: Adaptive T-cell immunity and tumor antigen recognition; 2 Gail D. Sckisel, Arta M. Monjazeb, Annie Mirsoian, Anthony E. Zamora, Steven Grossenbacher, and William J. Murphy: Impact of aging and body mass on cancer immunotherapy outcomes; 3 Thomas C.C. Tan, Jean-Marc Doisne and Francesco Colucci: The potential of natural killer cells in cancer immunotherapy; 4 Russell Hughes and Munitta Muthana: The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy; 5 Natalia Aptsiauri, Angel M. Garcia-Lora, Federico Garrido: Hard and soft loss of MHC class I expression in cancer cells; 6 A.G. Dalgleish: Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses; 7 Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg: Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.; 8 Thomas J. Sayers and Neil A Cross: Triggering death receptors as a means of inducing tumoricidal activity; 9 Jayakumar Vadakekolathu, Stephanie B. McArdle, David J. Boocock, and Amanda Miles: Identification of tumor antigens for clinical evaluation; 10 Peter L. Stern and Kenneth Oguejiofor: Viral antigens as targets for prophylactic and therapeutic intervention in cancer; 11 Constantin N. Baxevanis and Sonia A. Perez: HER-2/neu as a target for vaccine and antibody directed therapies; 12 Matteo Bellone, Sara Martina Parigi, and Elena Jachetti: Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model; 13 Per thor Straten, Dave Schrama, Jurgen C. Becker and Mads Hald Andersen: Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy; 14 M. Strioga and E. Tartour: Predictive biomarkers to better select patients for cancer immunotherapy; 15 Karishma Rajani, Vanessa Alonso-Camino, Nicolas Boisgerault, Richard Vile: Viral platforms for expression of tumour antigens in cancer immunotherapy; 16 Paul Moss: Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies; 17 L. G. Durrant, W. Xue, L. R. Machado, R. L. Metheringham, and V. A. Brentville: DNA vaccines; 18 Uzoma K. Iheagwaraa, Pamela L. Beattya, Chan Su-Wan Biancaa, Lora H. Rigattid, Ted Ross, and Olivera J. Finn: Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA); 19 Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-Ann Guinn: Vaccination against myeloid leukaemias using newly defined antigens; 20 Patrick A. Ott and F. Stephen Hodi: Immune-checkpoint blockade in cancer immunotherapy; 21 Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter: Multi-peptide cancer vaccines for clinical application; 22 Marco Donia, Eva Ellebaek, and Inge Marie Svane: Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma; 23 John S. Bridgeman and David E. Gilham: Chimeric antigen receptor gene therapy in cancer; 24 Claire Deligne, Sophie Siberil, and Jean-Luc Teillaud: The vaccinal effect of monoclonal antibodies in cancer therapy; 25 Gabriele Multhoff and Michael Stanglmaier: Antibody therapies: defining appropriate cell surface epitopes for targeting tumours; 26 Sophie Derniame and Aurore Saudemont: Adoptive lymphocyte (stem cell) therapy in cancer; 27 Tarik Regad and Morgan G. Mathieu: Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy; 28 Ludmila Muller and Graham Pawelec: Immune escape and aging of the immune system compromises the immune response to tumor antigens

Trade Policy 买家须知